IMUNON Reports Site Activation For IMNN-101 Phase 1 Vaccine Study
A second site at a tertiary center in Boston, MA is expected to be activated in the next few weeks.
Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment